93 related articles for article (PubMed ID: 33638323)
41. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
[TBL] [Abstract][Full Text] [Related]
42. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
43. Management of isolated recurrence after surgery for pancreatic adenocarcinoma.
Kim YI; Song KB; Lee YJ; Park KM; Hwang DW; Lee JH; Shin SH; Kwon JW; Ro JS; Kim SC
Br J Surg; 2019 Jun; 106(7):898-909. PubMed ID: 31162655
[TBL] [Abstract][Full Text] [Related]
44. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
45. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
46. Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma.
Salami A; Obaid T; Joshi ART
Am J Surg; 2019 Jan; 217(1):103-107. PubMed ID: 29807632
[TBL] [Abstract][Full Text] [Related]
47. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.
Murakawa M; Yamamoto N; Kamioka Y; Kamiya M; Kobayashi S; Ueno M; Morimoto M; Atsumi Y; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Morinaga S
In Vivo; 2020; 34(1):347-353. PubMed ID: 31882498
[TBL] [Abstract][Full Text] [Related]
48. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
49. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
50. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
[TBL] [Abstract][Full Text] [Related]
51. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma.
Duconseil P; Garnier J; Weets V; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2019 Jun; 17(1):95. PubMed ID: 31164144
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K; Kamigaki T; Okada S; Matsuda E; Ibe H; Oguma E; Naitoh K; Takimoto R; Goto S
Anticancer Res; 2018 Jul; 38(7):4353-4360. PubMed ID: 29970573
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
[TBL] [Abstract][Full Text] [Related]
54. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study.
Lygidakis NJ; Sgourakis G; Georgia D; Vlachos L; Raptis S
Ann Surg; 2002 Dec; 236(6):806-13. PubMed ID: 12454519
[TBL] [Abstract][Full Text] [Related]
55. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis.
McWilliams RR; Maisonneuve P; Bamlet WR; Petersen GM; Li D; Risch HA; Yu H; Fontham ET; Luckett B; Bosetti C; Negri E; La Vecchia C; Talamini R; Bueno de Mesquita HB; Bracci P; Gallinger S; Neale RE; Lowenfels AB
Pancreas; 2016 Feb; 45(2):311-6. PubMed ID: 26646264
[TBL] [Abstract][Full Text] [Related]
56. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience.
Takai S; Satoi S; Toyokawa H; Yanagimoto H; Sugimoto N; Tsuji K; Araki H; Matsui Y; Imamura A; Kwon AH; Kamiyama Y
Pancreas; 2003 Apr; 26(3):243-9. PubMed ID: 12657950
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy.
Ueno H; Okada S; Okusaka T; Ikeda M
Oncology; 2000 Nov; 59(4):296-301. PubMed ID: 11096341
[TBL] [Abstract][Full Text] [Related]
59. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
60. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis.
Hernandez JM; Tsalatsanis A; Humphries LA; Miladinovic B; Djulbegovic B; Velanovich V
Ann Surg; 2014 Jun; 259(6):1208-14. PubMed ID: 24169177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
